Seattle, WA (November 2015) – Periodontal disease is a chronic inflammatory disease that affects the gum tissue and other structures supporting the teeth. If left untreated, it can lead to tooth loss. Besides helping with tooth retention, successful periodontal treatment can help patients with diabetes to better control their disease. That is why OralDNA Labs, Inc. created MyPerioPath and MyPerioID.
With OralDNA we can finally test for the exact bacteria in ones mouth and see at what levels they are currently at. With such knowledge, we can customize the treatment plan to each individual patient for a much more effective way to combat periodontal disease! Specifically, the MyPerioPath test provides semi-quantitative levels of 11 different species of bacteria known to trigger periodontal disease. In addition to identifying the bacterial pathogens, the test provides a bacterial-related risk of disease progression and suggestions for suitable antibiotic therapy. The MyPerioID test detects genetic changes (DNA polymorphisms) that have been associated with increased incidence and/or progression of chronic periodontal disease in some studies.
To find out more about testing provided by OralDNA Labs, Inc., visit its website today at oraldna.com.
OralDNA® Labs is a specialty diagnostics company, created Access Genetics, designed to advance 21st century laboratory diagnostics in oral medicine. They are accomplishing this by providing reliable and definitive clinical tests that guide dental professionals in detecting and diagnosing disease at an earlier, more treatable stage.